ClinicalTrials.gg
CompletedNCT00376064Updated Mar 6, 2017

Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly

A Phase 4 interventional study of Octreotide acetate and cabergoline/Octrotide and Somavert in Acromegaly, sponsored by Novartis Pharmaceuticals. Completed at 16 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-03-06.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies testing octreotide in Acromegaly — 1 open to participants now, 1 under way, 1 of them phase 3. Octreotide · Acromegaly.

Enrollment
20th of 25
20 · median 56
Started
2006
with 1 other
Phase 4
10 of 25
none open now
Registered
8th of 25
by date
Lead sponsor
5 of 25
Novartis Pharmaceuticals

Among the 25 studies testing octreotide in Acromegaly, this one is the 20th largest by enrollment, is one of 2 that started in 2006, is one of 10 in phase 4, and was the 8th registered.

Acromegaly

202 studies on the registry are indexed under Acromegaly; 19 are open to participants now.

Browse Acromegaly studies →

Open to participants now

1 of the 25 studies testing octreotide in Acromegaly is open now. Recruiting first, the newest first:

About octreotide

Octreotide: first FDA approval 1988 (SANDOSTATIN), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 14 Acromegaly studies recruiting now, 7 (50%) set no upper age limit and 5 (36%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing octreotide in Acromegaly, or all of them as a file.
02

Study summary

This study will investigate the efficacy of a combination treatment with octreotide acetate and cabergoline in acromegalic patients that are only partially responsive to a somatostatin analog monotherapy

03

Conditions studied

  • Acromegaly

Keywords

  • Growth hormone (GH)
  • IGF-1
  • Acromegaly
  • Pituitary adenoma
  • Brain tumor
  • Brain cancer
  • Octreotide acetate
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female patients (> 18 years) with prior surgery of micro- or macroadenoma of the pituitary.
  • At least 6 months chronic treatment with 30mg octreotide (long acting release).
  • Partial responsiveness, which is defined as follows: at any one point within the 6 months monotherapy with 30mg/month octreotide (long acting release) the patient must have experienced a decrease in GH and IGF-1 of at least 25% as compared to pre-monotherapy values (= baseline). Note: For efficacy analysis GH- and IGF-1-values measured in the central laboratory at visit 1 (=study baseline) will be used.
  • Lack of suppression of GH nadir to \< 1.0 µg/L, after oral administration of 75 g of glucose (OGTT) and IGF-I levels at least 10% above the normal value ± 2 SD (adjusted for age and gender; Brabant 2003) must be proven within 4 weeks prior to visit 1. However, if acromegaly symptoms are inadequately controlled as defined in the acromegaly comorbidities and symptom evaluation (as judged by the investigator), an abnormal GH or IGF-1-value as defined above is sufficient.
  • Patient's written .

Exclusion criteria

Exclusion criteria:

  • Requires surgery for recent significant deterioration in visual fields or other neurological signs, which are related to the pituitary tumor mass.
  • Radiotherapy planned or radiotherapy for acromegaly within the last 2 years.
  • Symptomatic cholelithiasis that is .
  • Receiving treatment with dopamine agonists within the last 6 months or prior treatment with GH-receptor-antagonists.
  • Patients with renal insufficiency, Raynaud-Syndrome or gastrointestinal ulcer/ bleeding cannot be included in the study or psychose in anamnesis.

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    SMS995 + Carbegolin, Somavert + SMS995

    Drug: Octreotide acetate and cabergoline/Octrotide and Somavert

Interventions

06

What researchers measure

Primary outcomes

  1. Biochemical control (% of patients) as measured by GH- and IGF-1-values (baseline, EOS)

    Time frame: 8 months

Secondary outcomes

  1. Effect of tumor size

    Time frame: 8 months

  2. Biochemical control (mean, normalization) as measured by GH- and/or IGF-1-values

    Time frame: 8 months

  3. Control clinical of symptoms of acromegaly

    Time frame: 8 months

  4. Quality of Life assessment

    Time frame: 8 months

  5. Safety and tolerability as assessed by frequency of AEs

    Time frame: 8 months

07

Study locations

16 sites
  • Novartis Investigative Site
    Aachen, Germany
  • Novartis Investigative Site
    Berlin, Germany
  • Novartis Investigative Site
    Bochum, Germany
  • Novartis Investigative Site
    Erlangen, Germany
  • Novartis Investigative Site
    Essen, Germany
  • Novartis Investigative Site
    Greifswald, Germany
  • Novartis Investigative Site
    Heidelberg, Germany
  • Novartis Investigative Site
    Koln, Germany
  • Novartis Investigative Site
    Leipzig, Germany
  • Novartis Investigative Site
    Marburg, Germany
  • Novartis Investigative Site
    Muenchen, Germany
  • Novartis Investigative Site
    Oldenburg, Germany
  • Novartis Investigative Site
    Regensburg, Germany
  • Novartis Investigative Site
    Tubingen, Germany
  • Novartis Investigative Site
    Ulm, Germany
  • Novartis Investigative Site
    Wurzburg, Germany
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2006 and a primary completion of Jan 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2006
First posted
Sep 14, 2006
Start
Mar 2006
Primary completionActual
Jan 2010
Last update
Mar 6, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00376064
Responsible party
Sponsor
First posted
Sep 14, 2006
Start date
Mar 2006
Primary completion
Jan 2010
Last update
Mar 6, 2017

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmeceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Octreotide · Cabergoline · Pegvisomant

Start the discussion